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Abstract
Cardiac progenitor cells (CPCs) isolated as cardiospheres (CSs) and CS-derived cells (CDCs) are a promising tool for cardiac cell therapy in
heart failure patients, having CDCs already been used in a phase I/II clinical trial. Culture standardization according to Good Manufacturing Prac-
tices (GMPs) is a mandatory step for clinical translation. One of the main issues raised is the use of xenogenic additives (e.g. FBS, foetal bovine
serum) in cell culture media, which carries the risk of contamination with infectious viral/prion agents, and the possible induction of immunizing
effects in the final recipient. In this study, B27 supplement and sera requirements to comply with European GMPs were investigated in CSs and
CDCs cultures, in terms of process yield/efficiency and final cell product gene expression levels, as well as phenotype. B27 free CS cultures
produced a significantly reduced yield and a 10-fold drop in c-kit expression levels versus B27+ media. Moreover, autologous human serum
(aHS) and two different commercially available GMP AB HSs were compared with standard research-grade FBS. CPCs from all HSs explants
had reduced growth rate, assumed a senescent-like morphology with time in culture, and/or displayed a significant shift towards the endothelial
phenotype. Among three different GMP gamma-irradiated FBSs (giFBSs) tested, two provided unsatisfactory cell yields, while one performed
optimally, in terms of CPCs yield/phenotype. In conclusion, the use of HSs for the isolation and expansion of CSs/CDCs has to be excluded
because of altered proliferation and/or commitment, while media supplemented with B27 and the selected giFBS allows successful EU GMP-
complying CPCs culture.
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Introduction
During the last decade, fast-paced advancements in regenerative
medicine are offering novel promising therapeutic tools such as car-
diac cell therapy, which is emerging as an effective personalized treat-
ment for end-stage heart failure (HF) patients [1–4]. Considering the
social and financial cost of HF in western countries and its increasing
incidence as a chronic and epidemic condition, there is great interest
in developing new effective approaches to overcome the final patho-
logical mechanism, which is the loss of contractile tissue as a result
of cardiomyocyte death. To achieve successful regeneration, cell
sources are needed with indisputable cardiomyogenic differentiation
potential and resident cardiac progenitor cells (CPCs), which have
been tested in many animal models, and recently also in clinical set-
tings, seem to have the most promising potential [5–8]. Three clinical
trials for cardiac regeneration by resident CPCs have been started so
far: CADUCEUS (NCT00893360) [9], SCIPIO (NCT00474461) [10]
and ALCADIA (see NCT00981006 on www.clinicaltrial.gov) [11], rep-
resenting a solid proof of concept in terms of feasibility, safety,
reduction in infarct scar, therapeutic regeneration and functional
recovery.
Clinical translation requires protocol optimization in compliance
with current Good Manufacturing Practices (cGMPs) for cell prepa-
ration. Despite shared international guidelines, national regulations
(according to European Directives for EU countries, 2007/1394/EC)
require testing, strictly proving the necessity of the proposed protocols
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and reagents. One of the most important issues involved is the use
of supplements of xenogeneic origin for human cell culture [12].
Thus, careful evaluation of the minimal reagents requirements to
grant the expected cell yield and phenotype needs to be performed.
Foetal bovine serum (FBS) represents the most commonly used cell
culture supplement to provide the vital nutrients, toxin scavengers
and growth factors necessary to maintain mammalian cells in vitro.
Nevertheless, lot variability, the risk of contamination with infectious
viral or prion agents, and the possible induction of immunizing
effects in the final recipient require the investigation of possible
replacements for clinical-grade preparations [13–15]. For many cell
types (e.g. mesenchymal stem cells, endothelial progenitors, adi-
pose-derived stromal cells), other supplements, such as human AB
or cord blood serum and platelet lysate (PL), have been shown to
be valid FBS substitutes [16–19]. Nevertheless, effective alternatives
with the same wide acceptability are still missing, and it is very
often impossible to exclude its use without significant changes in
cell culture efficiency [12]. In this case, all possible precautions
must be implemented, in terms of FBS origin, preparation and pre-
cautionary pathogen inactivation (see EMA ‘Note for Guidance on
the Use of Bovine Serum in the Manufacture of Human Medicinal
Products’ at www.ema.europa.eu). The same infective and immuno-
genic issues and risks obviously exist for any other xenogenic and/
or artificial media additive, which has to be GMP compliant.
One of the CPC populations tested so far for cardiac cell therapy
(CADUCEUS trial) is derived through the cardiosphere (CS) protocol
[20, 21]. CSs are spontaneous 3D structures, housing undifferenti-
ated proliferating cells in their core and differentiating progenitors of
cardiovascular lineages in their periphery. They resemble a niche-like
microenvironment [22, 23] inducing muscle specification [24] and
forming through an epithelial-to-mesenchymal transition (EMT)-med-
iated process [25], where CPCs coexist with mesenchymal support-
ing cells. Cardiosphere-derived cells (CDCs) [26] can be efficiently
expanded as monolayers, and are able to form secondary CSs
(IICSs) when plated again in the appropriate conditions [21]. Cardiac
progenitor cells in the form of both CDCs and IICSs have been tested
in many animal models of cardiac cell therapy for HF [7], and CDC
also in a clinical trial [9]. Both CPC forms exert therapeutic effects,
although multiple lines of evidence suggest that the three-dimen-
sional form (i.e. CSs and IICSs) is more efficient [22, 27].
The original formulation of the CS protocol includes FBS, B27
supplement and recombinant growth factors at various steps of the
culture process. For some components, an important role in CSs and
CS-derived cells (CDCs) [26] phenotype and function has been
already recognized, that is thrombin [28] and EGF [29]. For FBS and
B27 supplement, though, a thorough assessment of their possible
replacement in media recipes has not been performed yet. In this
study, we first investigated the effect of B27 free culture on CSs
yield and phenotype. Then, we tested multiple serum alternatives to
standard research-grade FBS, to find a possible GMP-grade replace-
ment in compliance with European directives and standards. We
analysed each step of the culture protocol (or until possible) to verify
that the GMP-complying formulations tested would allow the same
outcome (yield, phenotype) as the consolidated research-grade
protocols.
Materials and methods
Cell culture
Human CPCs were isolated through the biopsy-derived explant
method, as previously described [21]. Surgical auricola biopsies were
obtained from 19 different patients (myocardial revascularization or
aortic/mitral valve repair/replacement; Table S1) during clinically indi-
cated procedures after informed consent, in an institutional review
board–approved protocol. Cardiospheres were grown on poly-D-Lysine
(BD Biosciences, Franklin Lakes, NJ, USA)–coated plates in CS-growth
medium (CGM): 35% IMDM and 65% DMEM/F-12 Mix, 3.5% serum,
1% penicillin-streptomycin, 1% L-glutamine, 0.1 mM 2-mercaptoetha-
nol, 1 U/ml thrombin (Sigma-Aldrich, St. Louis, MO, USA), 1:50 B-27
(Invitrogen, Carlsbad, CA, USA), 80 ng/ml bFGF, 25 ng/ml EGF and
4 ng/ml cardiotrophin-1 (Peprotech, Rocky Hill, NJ, USA). Primary ex-
plants and CDCs were cultured on fibronectin (Sigma-Aldrich)-coated
flasks in complete explant medium (CEM): IMDM, 1% penicillin-strep-
tomycin, 1% L-glutamine, 0.1 mM 2-mercaptoethanol, serum as spec-
ified in each data set. IICSs were obtained by re-plating CDCs in
CGM on poly-D-lysine–coated multi-wells at a density of 1 9 104
cells/cm2. For each biopsy, tissue was equally divided into the differ-
ent conditions tested, always maintaining a culture with standard FBS
conditions as a positive biological control and reference. The different
commercial sera tested are as follows: research-grade FBS (Lonza,
Basel, Switzerland), GMP-grade human AB sera (Starfish; Lonza),
gamma-irradiated GMP-grade FBSs of Australian origin (Lonza; Gibco,
Carlsbad, CA, USA; Hyclone, Waltham, MA, USA). For human sera, in
some experiments, one aliquot was subjected to heat inactivation
(56°C for 30 min.). For the B27 set of experiments, outgrowth cells
from the same explants in research-grade FBS (Lonza) were seeded
in CGM with or without B27; both B27+/ CDCs were cultured in
CEM, and then corresponding IICSs were obtained plating again in
B27+/ CGM.
Human serum preparation
Autologous serum was obtained by standard procedures of blood cen-
trifugation and clotting, with an approximate volume yield of 50%.
Cell proliferation and yield
Proliferation was quantified in a time-course analysis by WST8 incuba-
tion (Cell Counting Kit; Alexis Biochemicals, San Diego, CA, USA) and
absorbance reading, according to the manufacturer’s instructions; sig-
nal was normalized to that of day 0 after cell seeding (1000 cells per
well). Based on reference standard curves (data not shown), in our
setting, an approximate 2.6-fold increase in normalized signal corre-
sponds to a population doubling. CSs yield was calculated 1 week
after seeding by semi-automatic particle count performed by ImageJ
software on at least 8 random fields per condition per cell line,
normalized to each corresponding standard FBS culture, and finally
averaged among biological replicates. CSs dimension was calculated
by ImageJ measurements of the average diameter on at least 20 ran-
dom CSs per condition per cell line, normalized to each corresponding
standard FBS culture, with final averaging among biological replicates.
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RNA extraction and realtime PCR
RNA was extracted with column-based kits (Qiagen, Venlo, the Nether-
lands). Reverse transcription was performed on 500 ng starting RNA
(Qiagen) in a 20-ll reaction, and 1 ll of cDNA product was then sub-
jected to realtime PCR with Sybr Green Supermix in a MiniOpticon
instrument equipped with CFX software (Bio-Rad, Hercules, CA, USA)
for 40 thermal cycles (95°C for 10 sec., 56/58°C for 10 sec., 72°C for
30 sec.; see Table S2 for primers sequence and annealing tempera-
tures). All primers sets were previously tested for optimal efficiency
and all reactions were analysed by melting curves at the end to con-
firm product specificity. Each reaction was performed in triplicate. The
DDCt method was used for relative quantification, using GAPDH as
the housekeeping gene [30], and the expression levels of cells in
standard culture conditions (B27+ or FBS) for each biological replicate
as the reference for normalization.
Immunofluorescence
Cells were fixed for 10 minutes with 4% paraformaldehyde at 4°C, per-
meabilized with 0.1% Triton X-100 (Sigma-Aldrich) in PBS with 1%
BSA, then blocked in 10% goat serum, incubated overnight at 4°C in
1% goat serum with primary antibodies and then incubated for 2 hrs at
room temperature with secondary antibodies and Topro3 nuclear dye
(Invitrogen). Slides were mounted in Vectashield medium (Vector Labo-
ratories, Burlingame, CA, USA) and confocal fluorescence imaging was
performed on a TCS DMIRE 2 Leica microscope, equipped with LCS
A
C
D
B
Fig. 1 B27 supplement is required to
maintain standard cardiospheres (CSs)
culture yield and gene expression profile.
Primary and secondary CSs yield and
dimension (A) were altered in B27 CGM,
expressed as percentage of effect, normal-
ized to B27+ CGM (n = 3). Cell prolifera-
tion, quantified by WST colorimetric
assay, of CS-derived cells (CDCs) from
both B27+/ was comparable (B). Repre-
sentative images of B27+/ CSs are
shown in C. Gene expression analysis by
realtime PCR for multiple markers of
stemness and cardiovascular differentia-
tion (D) revealed no differences in the
profile of B27+/ CDCs, while a dramatic
drop in c-kit levels in B27 IICSs was
detectable (n = 3 each). The marked size
of error bars for c-kit and TnI in (D) is
due to the fact that in one replicate,
expression levels were undetectable.
#P < 0.05 versus B27+. *P < 0.001 ver-
sus B27+. Scale bars = 100 lm.
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Lite Software (Leica, Solms, Germany). Incubation with secondary anti-
bodies alone did not give any detectable background signal.
Statistical analysis
All results are presented as mean value  SEM, unless specified. Signifi-
cance of difference between any two groups was determined by two-sided
Student’s t-test, and a final value of P < 0.05 was considered significant.
Results
B27 supplement
Explant-derived cells (EDCs) from three different patients were plated
in CGM with or without B27, and CSs were obtained. CDCs from both
B27+/ were cultured in CEM, and then IICSs were obtained again in
the corresponding B27+/ CGM. Primary and secondary CSs yields
in B27 compared with B27+ were significantly reduced to
32.8  6.9% and 46.2  12.1% respectively (Fig. 1A), whereas the
average diameter of the spheres after 7 days of culture was slightly
higher in B27 samples: 135.5  4.6% in CSs and 139.8  10.1%
in IICSs (Fig. 1A). Representative bright field images of the cultures
are shown in Figure 1C. CDCs obtained from both culture conditions
displayed similar growth rate (Fig. 1B), despite the absolute yield
being obviously lower for B27. Then, we analysed the gene expres-
sion profile of CDCs and IICSs from B27+/ cultures. Realtime PCR
results are shown in Figure 1D. The expression levels of the genes
analysed, normalized to the levels of B27+ cultures, were unchanged
in CDCs, suggesting no significant phenotypic shift maintained after
the primary CS stage. Conversely, trends in genes modulation were
detectable in IICSs derived from B27 CSs and cultured again with-
out B27, with a 10-fold dramatic drop in c-kit expression levels
A
B C
Fig. 2 Autologous serum is not able to
support cardiospheres (CSs) formation
after primary explant. Representative
images of explant cultures show rapid ini-
tial growth in autologous human serum
(aHS) compared with foetal bovine serum
(A), and higher cell yield (n = 5) in terms
of harvest of CS-forming cells (B). Once
plated to form CSs, though, cells in aHS
stopped proliferating (C), as demonstrated
by WST assay (n = 5). #P < 0.05. Scale
bars = 50 lm.
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(P < 0.001), suggesting a reduction in the stemness potential of
IICSs. Analysis of Hsps expression levels suggests no increase in cell
stress. Thus, despite no memory of previous B27 starvation seems to
be detectable in CDCs at the mRNA level for the markers analysed,
B27 removal at IICSs stage significantly affects cell yield and their
typical gene expression profile.
Autologous human serum
Explants from five different patients were divided into equal tissue
amounts and plated in two different CEM, one with normal FBS and
the other supplemented with 20% autologous human serum (aHS).
Primary cultures with aHS grew much quicker than FBS during the
first 3 weeks (Fig. 2A), and the average EDCs yield per harvest was
significantly higher (Fig. 2B). Despite this, once plated to form CSs in
CGM supplemented with the corresponding serum (FBS or aHS), cells
from aHS explants stopped growing, as shown by the proliferation
curve (Fig. 2C), without yielding any significant amount of cells for
further experiments.
Commercial human AB serums
Next, we examined the replacement of FBS with commercially avail-
able standardized AB human sera. We tested two products from two
different companies on explants from three different patients. Fig-
ure 3A shows a representative comparative timeline of cultures in
the two HSs and FBS as control. As observed for aHS (Fig. 2A, left
panels), the explants in commercial HSs seemed to grow quicker, or
at least in parallel, compared with standard CEM (Fig. 3B, Table S3).
Nevertheless, after 4–5 weeks of primary culture and after one to
two harvests of EDCs, outgrowth cells in HS explants gradually
changed their morphology (Fig. 3B, right panels), increased cell size,
took a flat vacuole-rich shape, and stopped proliferating and migrat-
ing, preventing further harvests from the primary culture. On the
contrary, in standard FBS, explants outgrowth cells kept their origi-
nal morphology, and bright round proliferating cells could still be
detected at 6 weeks of culture, allowing up to four harvests from
the same explant. As demonstrated in the timeline (Fig. 3A), explant
in FBS was harvested approximately every week up to four times,
whereas explants in HS could not be harvested anymore after the
fifth week. The average time necessary for the first harvest, the time
between one harvest and the following, and the average number of
harvests possible from the same primary explant are summarized in
Table S3. Average yield and dimension of CSs obtained from HS ex-
plants, and grown in CGM with HS, were comparable to those from
FBS (Fig. 4A), despite significant variability among patients. Repre-
sentative images of CSs cultures in different conditions are shown
in Figure 4B. When plated as CDCs, HS cells displayed a signifi-
cantly reduced proliferation rate compared with FBS (Fig. 4C). More-
over, even considering the best performing HS (i.e. Starfish),
comparative growth curves in 3% or 20% serum showed a clear
dose-dependent inhibitory effect of HS on CDCs proliferation
(Fig. 4D). In fact, lowering FBS from 20% to 3% decreased
proliferation, as expected, while for HS, an opposite trend was
observed, with a significantly higher proliferation rate at 3% versus
20%. Reduced proliferation of CDCs in HS was consistent with the
observed morphology (Fig. 4E): as seen in primary explant cultures,
CDCs in HSs assumed a senescent-like shape and eventually
stopped proliferating at early passage.
Gene expression analysis was performed on CDCs from HS cul-
tures, and normalized to standard FBS (Fig. 5A). Smooth muscle
actin (SMA) and Thy1 levels were significantly down-regulated in
both HSs, while cardiac markers, such as TnI and Cx43, were basi-
cally unaffected. Analysis of Hsps expression levels suggests no
changes in cell stress. Interestingly, KDR was dramatically up-regu-
lated in both HSs, suggesting that HSs could encourage endothelial
commitment of CDCs. This hypothesis was further supported by
immunofluorescence analysis of CSs (Fig. 5B), which showed, espe-
cially for Starfish serum, a strong and homogeneous positivity for
CD31. The expression of TnI and Nkx2.5 proteins was confirmed by
immunofluorescence as well.
A
B
Fig. 3 Cultures with commercial AB human sera gradually displayed
senescence features. Initial cell growth in primary explants was compa-
rable between foetal bovine serum (FBS) and HSs, as demonstrated by
time-course of cell harvests (H) up to H2 (A) and similar morphology in
culture (B, left column). Nevertheless, after 5–6 weeks, HS outgrowth
cells gradually ceased proliferating, preventing further harvests (A) and
assuming a flat vacuole-rich morphology (B), whereas in control ex-
plants, round phase-bright proliferating cells could still be detectable
(black arrows), reaching H4 (A). Scale bars = 50 lm. H: harvest of car-
diosphere-forming cells from primary explant culture. P: passage of CS-
derived cells.
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To test whether the HS negative effect could be reduced or
avoided by decreasing serum concentration from the beginning of the
protocol, an attempt was made to culture primary explants in 1% or
3% HS, but no cells could be obtained (Figure S1).
Moreover, to test whether residual complement activity could
be responsible for the growth arrest and phenotype change
observed, we tested Lonza HS after heat inactivation treatment.
CDCs from normal FBS explants were plated for 7 days in FBS
5% as control, Lonza HS 20% or 5%, Lonza HS heat inactivated
20% or 5%, and gene expression analysis was performed by real-
time PCR and normalized to standard FBS 20% conditions. As
shown in Figure 5C, even on normal healthy CDCs, 1 week of cul-
ture in HS was enough to significantly modulate gene expression.
In Lonza HS 20%, SMA, ckit, TnI, Cx43, Thy1 and Gata4 were sig-
nificantly down-regulated, while KDR levels were unchanged, con-
firming again a possible preferential endothelial commitment
exerted by HS. As observed for cell proliferation, a dose-dependent
effect was detected, as demonstrated from the analysis of the Lon-
za HS 5% sample, where most genes inverted the down-regulation
trend. Genes down-regulation was still detectable in heat-inacti-
vated HS, displaying again an inverted dose-dependent trend from
20% to 5%. Nevertheless, important genes, such as SMA, c-kit
and Cx43, were still significantly down-regulated compared with
standard FBS conditions.
Gamma-irradiated FBS
As human sera exerted inhibitory/toxic effects on our cellular model
and altered commitment, we next examined the possibility of using
GMP gamma-irradiated FBS (giFBS) of Australian origin. We evalu-
ated sera from three different companies, Lonza, Gibco and Hyclone,
on eight different biopsies overall. Considering Gibco and Lonza, we
were able to isolate CPCs from three out of five and two out of five ex-
plants, respectively, while all control explants in FBS yielded success-
ful CPCs isolation. With these two sera, we observed again a trend of
senescent-like morphology with time in culture (Figure S1A). Average
CSs yield and dimension were not significantly different from stan-
dard FBS (Figure S1B), but the overall rate of successful explants
was clearly unsatisfactory. Hyclone explants were all successful, with
comparable timing (Table S3) and yield (Figure S1B) versus standard
FBS, and did not display altered cell morphology with time in culture
(Figure S1A). Average yield and dimension of CSs obtained from
successful giFBS explants were comparable to those from standard
A B
C
E
D
Fig. 4 Cardiospheres (CSs) yield and cell
proliferation in AB human sera cultures.
CSs yield and dimension, expressed as
percentage of effect versus foetal bovine
serum (FBS), were comparable in human
serum (HSs) cultures (A), until CS-form-
ing cells could be harvested. Representa-
tive images of CSs from different sera are
shown in B. Nevertheless, at the CS-
derived cell (CDC) stage cells stopped
proliferating compared with control cul-
tures in FBS (C), and such effect was
dose dependent, as demonstrated by
comparing cultures in 3% and 20% sera
(D). Representative images of CDCs in
HSs and FBS are shown in E. Scale
bars = 50 lm. *P < 0.001 versus HSs.
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FBS (Figure S1B). Proliferation of CDCs was significantly reduced in
cultures with Lonza and Gibco sera (Figure S1C), while Hyclone giFBS
performed as control. Thus, Hyclone giFBS can be considered the
best performing GMP serum, as far as yield and cell proliferation are
concerned. Then, we compared the phenotype and gene expression
between Hyclone and control FBS. Realtime PCR analysis of Hyclone
CDCs and IICSs revealed no statistically significant modulation in
expression levels of the genes analysed (stemness, lineage and stress
related) when normalized to control FBS, despite trends towards up-
regulation in IICSs, particularly for c-kit (Fig. 6A). Immunofluores-
cence analysis (Fig. 6B) detected similar morphology and phenotype
between the two sera, with the same abundance of positive cells and
antigen intracellular distribution.
Discussion
Cardiac cell therapy has moved very quickly towards clinical transla-
tion. Many clinical trials designed for the treatment of HF have been
completed in the past 10 years with different adult stem cells popula-
tions (e.g. hematopoietic, mesenchymal and skeletal) [2, 7, 31],
including recently resident autologous CPCs [9, 10]. Clinical transla-
tion requires compliance with GMP quality standards for cell produc-
tion, and protocols adjustment may not always be straightforward. In
particular, the use of FBS in media, as a xenogenic non-standardized
ingredient, is still under discussion, being nevertheless widely used
for the clinical-scale isolation, expansion and production of different
A
B
C
Fig. 5 Cardiac progenitor cells in AB
human sera displayed altered commitment
towards cardiovascular lineages. Gene
expression analysis on CS-derived cells
(CDCs; A), normalized to standard foetal
bovine serum (FBS) conditions, revealed a
significant up-regulation of KDR in human
sera (HSs), and a significant down-regula-
tion of SMA and Thy1, suggesting a pre-
ferred commitment towards an endothelial
lineage. Immunofluorescence and confocal
analysis of primary cardiospheres (B) fur-
ther evidenced a higher expression of the
endothelial marker CD31 in HSs, particu-
larly in Starfish samples. CDCs obtained
from standard FBS were cultured for
1 week in HS 5% or 20%, subjected or
not to heat inactivation (HI). Gene expres-
sion analysis (C) revealed that 1 week of
HS exposure was enough to significantly
down-regulate multiple genes versus FBS,
such as SMA, c-kit, TnI, Cx43, Thy1 and
GATA4. As observed for cell proliferation,
the effect was dose dependent. Heat inac-
tivation partially recovered the effect, but
important genes, such as SMA, c-kit and
Cx43, were still significantly down-regu-
lated compared with standard FBS condi-
tions. Scale bars = 50 lm. *P < 0.001
versus FBS.
630 ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
stem cells. Despite multiple washes to remove FBS contaminants
from the final cell product are routinely performed, nevertheless, the
risk of adverse reaction in final recipients persists. Concerning cell
populations of haematopoietic or bone marrow origin under clinical
evaluation (e.g. endothelial progenitor cells, mesenchymal stem
cells), many studies have been already performed, aiming at optimiz-
ing cell culture conditions [12, 14, 15, 17, 32]. For example, the use
of aHS with human T cells in vitro extends their proliferative lifespan,
clonogenicity and telomerase activity [33]. MSCs from different
sources have been successfully cultured in HS [34], PL [18] or cord
blood serum [16]. Concerning resident CPCs, there is still no litera-
ture focused on comparing different culture conditions, media, sup-
plements or growth factors.
We first examined the role of the B27 supplement in CSs culture
(Fig. 1), comparing CSs, CDCs and IICSs obtained from B27+ or
B27 CGM. B27 is a chemically defined, widely used ingredient first
introduced in neurobiology research, and nowadays described in the
formulation of media for multiple stem cell types, such as neuronal
stem cells [35], neurosphere-derived cells [36], spermatogonial stem
cells [37] and retinal stem cells [38]. It contains vitamins, antioxi-
dants, essential fatty acids and hormones (e.g. insulin, progesterone,
T3); it is commercially available as GMP-grade and has been already
used in clinical-scale cell productions [39–41].
B27 granted significantly higher CSs yield. CDC proliferation rate
and gene expression levels seem not to have memory of previous
B27 starvation, displaying no difference compared with CDCs from
standard B27+ CSs. IICSs, though, showed again altered yield and
morphology, and gene expression profile when cultured in B27 free
CGM. The significant drop in c-kit expression level (Fig. 1D), suggest-
ing a depletion in stemness properties or pool inside the CS, is of par-
ticular interest and not desirable, given the superior regenerative and
therapeutic potential of CSs versus CDCs [22, 27]. Thus, our data
suggest an important contribution of B27 to the distinctive phenotype
of CSs and IICSs.
Next, we attempted replacing FBS with aHS (Fig. 2), but despite
promising initial growth of primary explants and EDCs yield, early
growth arrest at the CS stage in aHS cultures prevented successful
culture completion. In other cell models for regenerative medicine,
such as MSCs [42], human Schwann cells [43] or Tenon’s fibroblasts
[44], aHS outcome was comparable to FBS, but, based on our data,
with CSs cultures it cannot be considered as a valid option.
To avoid the possible influence of patients’ variability and/or
because of their ‘pre-harvest’ clinical conditions, we tested commer-
cial GMP-grade AB human sera from two companies: Lonza and Star-
fish. Despite similar initial growth of primary explants compared to
standard FBS, EDCs from HSs acquired a senescent-like morphology
(Fig. 3) with time in culture and stopped proliferating, significantly
reducing the number of harvests and the cumulative yield from ex-
plants (Table S3), despite similar CS yield and dimension in the first
possible harvests (Fig. 4). CDC proliferation was significantly
impaired in both HSs, particularly in Lonza HS, and displayed a
reverse dose–response trend for serum concentration (Fig. 4D), sug-
gesting some kind of inhibitory and/or toxic effect. Gene expression
profile showed a significant up-regulation of KDR and down-regula-
tion of SMA and Thy1 in CDCs from HSs versus standard FBS
(Fig. 5A), suggesting a preferential endothelial commitment. This was
confirmed by immunofluorescence, and was particularly evident in
Starfish HS, where a striking CD31 positivity in the whole CS was
observed (Fig. 5B).
Successful stem cell cultures with AB HSs have been obtained
with MSCs [34, 45, 46] or dental pulp–derived stem cells [47]. Vari-
able results with AB HSs from different companies have been
observed for mesodermal progenitor cells [48], where interestingly a
small concentration of HSs in media was sufficient to change their
phenotype, whereas for Tenon’s fibroblasts for corneal regenerative
medicine AB HS failed to give successful cultures [44]. Nevertheless,
FBS has been also suggested to promote greater culture adaptation
and therapeutic potential of adipose-derived MSCs [49], highlighting
how variability in products and cell-type responsiveness are still open
issues for sera optimization in clinical-grade productions. Overall, our
results suggest that both autologous and AB commercial HSs are not
A
B
Fig. 6 Gene expression profile of cardiac progenitor cells cultured with
Hyclone giFBS. Realtime PCR analysis (A) detected expression levels
very similar to control for the genes analysed in Hyclone giFBS cul-
tures, with a trend towards up-regulation in IICSs for some markers,
such as c-kit. (B) Representative immunofluorescence panels for SMA,
c-kit, TnI, MHC and nkx2.5, showing similar abundance and antigen dis-
tribution in Hyclons giFBS compared to standard conditions. Scale bars =
20 lm.
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suitable for CPCs isolation and culture with the CS method, as they
are necessary in high concentration since the first culture stage (Fig-
ure S1), but seem to exert inhibitory/toxic effects at early stages of
culture, significantly reducing cell yield, and to alter the spontaneous
functional balance between vascular and cardiac commitment in CSs
and CDCs.
To try all possible alternatives to FBS, we tested some commer-
cially available serum-free formulation and PL as well, which have
been also described in other stem cell models [12, 19, 50–52], with-
out any success in primary explant culture or CS viability (data not
shown). Interestingly, sequential use of PL and HS has been shown
effective for cardiovascular tissue engineering approaches on colla-
gen scaffolds [53], but, despite CS being suitable for tissue engineer-
ing approaches as well [54, 55], our results suggest that this kind of
media formulation would not be effective with this cell model.
As xenogenic FBS cannot be replaced with human-derived supple-
ments in our culture system, we tested three different giFBSs.
Gamma-irradiation is the recommended virus-inactivation treatment
for FBS by EMA guidelines, while the Australian origin secures from
the risk of contamination from any major epidemic disease. Lonza
and Gibco giFBSs not always allowed successful CSs and CDCs cul-
tures (see results section), despite similar yield and morphology
when harvests were possible (Figure S1A and B). We observed again,
as for HSs, a senescent-like morphology with time in culture and
gradual growth arrest in explants (Figure S1A) and CDCs (Fig-
ure S1C). On the contrary, Hyclone giFBS had a 100% successful cul-
ture rate, comparable harvest timing/frequency (Table S3), explant
growth, CS yield (Figure S1), CDC proliferation rate, CDCs/IICSs gene
expression profile and phenotype (Fig. 6). Overall, it was the best per-
forming condition tested in our study, yielding completely satisfactory
cell number and quality.
In conclusion, our data contribute to highlighting the issue of how
the replacement of xenogenic media additives, such as FBS, is not
always possible and highly cell-type dependent. For EU cGMP-com-
plying isolation and production of CPCs in the form of CSs and CDCs,
the combination of B27 supplement with Hyclone giFBS is the best
performing protocol selected in our study. To our knowledge, this is
the first comparative analysis aimed at optimizing culture conditions
for the clinical translation of CPCs production under European cGMP
standards.
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